Gilead said it was working to build a consortium of manufacturing partners to help maximise global supply of the drug. - Reuters
BENGALURU (Rueters): Gilead Sciences Inc said on Tuesday (May 5) it was in discussions with chemical and drug manufacturers to produce its experimental Covid-19 drug remdesivir for Europe, Asia and the developing world through at least 2022.
The drugmaker did not disclose details about the companies.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
